Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | TP53 Y220C |
Therapy | PC14586 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 Y220C | Advanced Solid Tumor | predicted - sensitive | PC14586 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PC14586 treatment reactivated Tp53 function and resulted in cell cycle arrest in cancer cell lines harboring TP53 Y220C in culture, and led to complete cure in 80% of syngeneic xenograft models (AACR Annual Meeting Apr 2021, Session MS.LBA01, Abstract # LB006). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development | Full reference... |